Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WALANT With Versus Without Hyaluronidase for Hand Surgery
NCT07000058Phase 3
Key facts
- Status
- Active, not recruiting
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Countries
- 1
- Sponsor
- Misr University for Science and Technology
- Modality
- Therapeutic Enzymes
- Drugs
- hyaluronidase
01
Overview
Phase 3, randomised, double-blind trial of hyaluronidase (2 arms), sponsored by Misr University for Science and Technology. Primary endpoint: Onset time of analgesia. Started Jun 2025; status: active, not recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
WALANT with Hyaluronidase
Lidocaine 1% + Epinephrine 1:200,000 + Hyaluronidase 15 IU/ml + Bicarbonate
WALANT without Hyaluronidase
Lidocaine 1% + Epinephrine 1:200,000 + Bicarbonate
03
Who it enrols
Patients 18-60 years old scheduled for hand surgery with ASA class I or II. Excludes pregnant women, psychiatric illness, uncooperative patients, allergy to local anesthetics, cardiac arrhythmia, bleeding tendency, low flow finger perfusion (Burger/Raynaud's), connective tissue disease (Scleroderma), and malignancy or hand infection.
04
Endpoints
Primary
Onset time of analgesia
Secondary
Duration of postoperative analgesia
Pain intensity
The amount of morphine used
Amount of bleeding
Patient satisfaction
Beyond the preview
Go deeper on NCT07000058.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000058.